The efficacy and safety of ertapenem, 1 g once a day, for the treatment of community-acquired pneumonia (CAP) requiring parenteral therapy were compared with those of ceftriaxone, 1 g once a day, in 866 hospitalized adults randomized in two prospective, double-blind, multicentre studies. Patients were stratified according to Pneumonia Severity Index (≤3 or >3) or age (≤65 or >65 years). After ≥3 days of parenteral antimicrobial therapy, patients who had clinically improved could be switched to oral co-amoxiclav. The median durations of parenteral, oral and total therapy in the 658 clinically evaluable patients, of whom 88% were switched to oral therapy, were 4, 7 and 12 days, respectively, in both treatment groups. The most common pathogen was Streptococcus pneumoniae, of which 79% (143/181) were penicillin susceptible and 3.3% (6/181; three in each treatment group) were penicillin resistant. Cure rates for the two treatments were equivalent: 91.9% for ertapenem and 92.0% for ceftriaxone (95% confidence interval for the difference, adjusted for strata: -4.5 to 4.4). Cure rates in the different severity and age strata and bacterial eradication rates for both treatment groups were also similar. The most common drug-related adverse events in both treatment groups were diarrhoea and mild-to-moderate elevations in aminotransferase levels. The results of these studies demonstrate that ertapenem, 1 g once a day, was highly effective therapy for CAP in hospitalized adults with moderate-to-severe disease.
Introduction
Pneumonia is associated with considerable morbidity and mortality worldwide. It is the sixth and fifth leading cause of death in the USA and the UK, respectively. 1,2 In the USA, >4 million adults are diagnosed with community-acquired pneumonia (CAP) each year, resulting in >1 million hospitalizations and approximately 10 million days of work loss. [3] [4] [5] In the UK and the Netherlands, the annual incidence of CAP is estimated at 1-4 per 1000 population, and 5-20% of patients require hospitalization. 6, 7 The average case-fatality rate for hospitalized patients with CAP is ∼14%, but it varies from 2% to 30%, with higher rates in the elderly and in developing countries. 8 Establishing the aetiology of CAP is difficult. Many patients, especially the elderly and those who are dehydrated, cannot expectorate lower respiratory secretions and, therefore, do not produce specimens acceptable for bacterial culture. Even when suitable specimens are produced, culture results are not available for 2-3 days. Additionally, differentiating invasive from colonizing bacteria is often difficult. For these reasons, initial therapy for CAP is generally empirical, based on the most likely pathogens and local susceptibility patterns.
Ertapenem (formerly MK-0826; Merck & Co., Inc.) is a once-aday parenteral β-lactam agent licensed in November 2001 in the USA and in April 2002 in Europe, for the treatment of moderate-to-severe CAP and various mixed aerobic/anaerobic infections. This Group 1 carbapenem 9 has a focused spectrum of activity. Ertapenem has excellent in vitro activity (i.e. ≥90% of isolates have an ertapenem MIC less than or equal to the susceptibility breakpoint) against bacteria that, in general, are associated with community-acquired infections, such as methicillin-susceptible Staphylococcus aureus and many Haemophilus spp., streptococci, Enterobacteriaceae and anaerobes, but is usually not effective against Pseudomonas aeruginosa or enterococci, 10, 11 which are generally associated with nosocomial infections. Similar to other β-lactams, ertapenem is not indicated for the treatment of infections caused by Legionella species, Mycoplasma pneumoniae or Chlamydia pneumoniae.
In two large, independent but similarly designed clinical trials, ertapenem, 1 g once a day, was highly effective for the treatment of CAP and equivalent in efficacy to ceftriaxone, 1 g once a day. A 1 g dose of ceftriaxone is accepted therapy for CAP and has been shown to be effective in several previous clinical studies. [12] [13] [14] [15] Clinical success rates 7-14 days post-therapy for ertapenem and ceftriaxone, respectively, were 92.3% (168/182 patients) and 91.0% (183/201 patients) in the first trial, 16 and 91.0% (91/100 patients) and 91.8% (45/49 patients) in the second trial. 17 Combining the data from these two comparative trials, as reported here, strengthens the safety analysis and the analyses of efficacy by stratum and by specific pathogen.
Patients and methods

Study design
This analysis includes data from two previously reported prospective, double-blind (with in-house blinding), multinational studies conducted from July 1998 to May 2000. 16, 17 Written consent was obtained from all patients, and the institutional review board at each participating site approved the protocol. Randomization (1:1 ertapenem:ceftriaxone in one trial; 2:1 in the other), performed by following an allocation schedule using computer-generated random numbers, was stratified according to age (≤65 or >65 years) or Pneumonia Severity Index (PSI ≤3 or >3). The later incorporates an assessment of associated conditions, acute physiological changes and age; 18 a PSI of 4 or 5 indicates severe illness.
Patients
Hospitalized patients aged ≥18 years who had clinical and radiographic evidence of CAP were eligible for the study if they required initial parenteral antimicrobial therapy and if the infection was caused by a pathogen susceptible to the study drugs. To minimize the possibility of enrolling a patient with atypical pneumonia, patients aged <40 years were required to have purulent lower respiratory secretions with a predominant organism in the Gram-stained smear of sputum and/or a positive blood culture plus clinical and radiographic findings compatible with typical pneumonia.
Patients with any of the following were excluded from the study: pregnancy or lactation in women, history of serious allergy or intolerance to study therapy, residence in a nursing home, empyema, underlying structural lung abnormalities, lung malignancy, cystic fibrosis, nosocomial or ventilator-associated pneumonia, tuberculosis, legionellosis, any rapidly progressive disease, immunocompromising illness or therapy, the need for concomitant antimicrobials in addition to study therapy, acute hepatic failure, requirement for peritoneal dialysis or haemodialysis, a baseline pathogen resistant to either study drug, aspartate or alanine aminotransferase >6 times the upper limit of normal (ULN), bilirubin or alkaline phosphatase >3 times the ULN, absolute neutrophil count ≤1000/mm 3 , platelet concentration <75 000/mm 3 , haematocrit <25%, or coagulation tests >1.5 times ULN. Patients treated with a systemic antimicrobial agent for ≥24 h were excluded unless treatment failure was documented. Patients with a positive urine test for Legionella antigen were excluded unless the investigator attributed the positive result to an earlier Legionella infection and, on the basis of clinical signs and symptoms, believed that the current illness was due to a typical bacterial respiratory pathogen.
Antimicrobial therapy
Both ertapenem and ceftriaxone were given once a day, initially as a 1 g intravenous (iv) dose infused over 30 min. In one study, subsequent doses of either agent could be administered by intramuscular (im) injection. For patients with creatinine clearance of <1.8 L/h/1.73 m 2 not requiring dialysis, the ertapenem dose was 500 mg. Each day patients received one infusion of study antimicrobial and one infusion of colourmatched placebo.
At the discretion of the investigator, after 3 days of parenteral therapy, patients who met pre-specified clinical improvement criteria could be switched to oral co-amoxiclav. If the pathogen was resistant to co-amoxiclav or if the patient could not tolerate that agent, the investigator could select an appropriate alternative antimicrobial. The suggested total duration of parenteral plus optional oral therapy was 10-14 days.
Microbiological investigations
Tests done at baseline included Gram's stain and culture of sputum or other respiratory secretions, blood culture, and urine antigen assay or culture of sputum for Legionella species. Organisms isolated at baseline were identified at the site laboratory and classified by the investigator as pathogens or colonizers. Pathogens were tested for in vitro susceptibility to ertapenem, ceftriaxone and co-amoxiclav following NCCLS guidelines. 19 The susceptibility of Streptococcus pneumoniae to penicillin was determined by disc diffusion using a 1 µg oxacillin disc; nonsusceptibility was confirmed by penicillin Etest or broth microdilution. Staphylococci were tested for susceptibility to oxacillin and, if resistant, were considered resistant to all study drugs.
Clinical and microbiological assessments
Patients were evaluated at enrolment and daily thereafter while on parenteral study therapy. Clinical response was measured on days 3-5, when parenteral therapy was completed, 7-14 days post-therapy [test of cure (TOC) visit] and 21-28 days post-therapy. Microbiological response was based on recovery of a respiratory pathogen at study entry and documented or presumed eradication or persistence of that baseline pathogen at times of follow-up.
Populations for analysis
The treated population included all randomized patients who received one or more doses of study therapy. The clinical modified intent-to-treat (MITT) population was the subset of treated patients who met defined minimum requirements for the diagnosis of CAP. The microbiological MITT population included patients in the clinical MITT population for whom a baseline pathogen was identified and a microbiological response assessment was made. The clinically evaluable population was a subset of the clinical MITT population for whom information was sufficient to determine outcome and in whom the baseline pathogens (if identified) were susceptible to both study parenteral antimicrobial agents and did not include penicillin-resistant S. pneumoniae (PRSP). Patients with PRSP at baseline and who were otherwise evaluable were included in separate analyses. Microbiologically evaluable patients were those clinically evaluable patients in whom a baseline pathogen was identified.
Efficacy variables
The primary efficacy variable in this combined analysis was the clinical response assessment in clinically evaluable patients at the TOC visit. Additional clinical and microbiological efficacy assessments were carried out at other time points and in the clinical and microbiological MITT populations.
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Safety assessment
All patients who received one or more doses of the study therapy were evaluated for safety. Patients were monitored for adverse events (AEs) daily from the start of parenteral therapy until 14 days after completion of all (parenteral plus optional oral) study antimicrobial therapy. The investigator categorized the intensity of the AE (mild, moderate or severe) and the likelihood of its relationship to the study drug (definitely not, probably not, possibly, probably or definitely). Events categorized as possibly, probably or definitely related to study therapy were considered to be drug related. The tolerability of parenteral study drug at the local infusion site was evaluated daily by the investigator.
Statistical analyses
Results for each efficacy variable were analysed using an 'evaluablepatients-only' approach, which was the primary efficacy analysis, and a MITT approach, to support the primary analysis. The combined analysis reported here was designed to test for equivalence in efficacy of the ertapenem and ceftriaxone treatment groups. The 95% (two-sided) confidence interval (95% CI) for the difference (ertapenem minus ceftriaxone) in response rates between the two treatment groups was determined; in order to meet the definition for equivalence the CI had to contain zero and its lower limit could not be less than -10%. CIs were calculated using the normal approximation to the binomial distribution. The Cochran-Mantel-Haenzel approach was used to account for baseline stratification. The treatment by stratum interaction was investigated using the Breslow-Day test of homogeneity of odds ratios.
Results
Patients
The distribution of study patients is summarized in Figure 1 . Of the 866 patients randomized, 364 (75.4%) in the ertapenem group and 294 (76.8%) in the ceftriaxone group were clinically evaluable. Six patients, three in each treatment group, had PRSP. The most common reasons for patients not being clinically evaluable were failure to receive adequate study therapy, failure to have a TOC assessment in the appropriate time window and receipt of non-study concomitant systemic antimicrobial agents for reasons other than failure.
The demographic characteristics of all randomized patients and the clinically evaluable subpopulation are shown in Table 1 . In the randomized population, the two treatment groups were generally similar with respect to age, gender, race and severity of pneumonia. Nearly 40% of patients were >65 years of age and >25% had severe disease (PSI group 4 or 5). The clinically evaluable population appeared comparable to the randomized population (Table 1) , as did the microbiologically evaluable population and the respective MITT populations (data not shown).
Therapy
Most patients received study parenteral therapy by iv infusion. Among the clinically evaluable patients, 10 (seven who received ertapenem and three who received ceftriaxone) received one or more doses of study therapy by im injection. In the ertapenem and ceftriaxone groups, of the clinically evaluable population, 321 (88.2%) and 258 (87.8%), respectively, were switched to oral therapy [co-amoxiclav for most patients (92.9%) in both treatment groups]; and the median (range) durations of ertapenem and ceftriaxone therapy, respectively, were: parenteral, 4.0 (2-17) days and 4.0 (2-17) days; oral, 7.0 (1-18) days and 7.0 (2-15) days; total, 12.0 (3-21) days and 12.0 (3-22) days.
Baseline microbiology
A total of 288 pathogens was recovered from 241 (49.9%) patients in the ertapenem group, and 242 pathogens were recovered from 196 (51.2%) patients in the ceftriaxone group. One hundred and ninetysix (40.6%) patients treated with ertapenem and 162 (42.3%) patients treated with ceftriaxone were microbiologically evaluable, and from these patients, 217 and 190 bacteria, respectively, were recovered. The distribution of pathogens in the microbiological MITT and evaluable populations was generally similar (data not shown). The most common pathogen was S. pneumoniae, followed by Haemo- ii62 philus influenzae and Moraxella catarrhalis (shown for the evaluable patients in Figure 2 ). The susceptibility profiles of the pathogens in both groups were similar: almost all isolates were susceptible to ertapenem and ceftriaxone, except oxacillin-resistant S. aureus. Forty-nine patients (23 who received ertapenem, 26 who received ceftriaxone) were bacteraemic at baseline; S. pneumoniae was the isolate in 41 (83.7%) of these patients.
Efficacy
Results of the primary and supportive analyses, adjusted for strata, are shown in Table 2 . At the TOC assessment, 91.9% of the clinically evaluable patients in the ertapenem group and 92.0% in the ceftriaxone group were cured (95% CI, adjusted for stratum, -4.5 to 4.4), indicating that the two treatments were equivalent. Cure rates among clinically evaluable patients at discontinuation of parenteral therapy were nearly identical in both treatment groups (95.2% ertapenem versus 94.4% ceftriaxone) and were higher than at the TOC assessment. In the MITT populations, cure rates, although slightly lower than in the respective evaluable populations, were similar in the two treatment groups, supporting the results of the primary analysis. The reason for the lower rates was the more conservative approach used for the MITT outcome assessment, in which patients with inadequate clinical information (e.g. lost to follow-up) were considered to have an unfavourable outcome. Cure rates at the TOC assessment in the clinically evaluable population are shown by age category and PSI score in Table 3 . Success rates overall (92.0% ertapenem versus 91.8% ceftriaxone), as well as in the different subgroups, were similar in both treatment groups. In patients aged ≥75 years, cure rates were higher in those who received ertapenem (94.0%, 63/67 patients) than in those who received ceftriaxone (87.3%, 55/63 patients).
Clinical cure rates and bacterial eradication rates in the microbiologically evaluable population at the TOC assessment were comparable in both treatment groups for the major pathogens (Table 4 ). Among patients with pneumococcal pneumonia, the clinical and microbiological response rates were generally similar regardless of the penicillin susceptibility test result. All six patients with PRSP had favourable clinical and microbiological outcomes. Of the bacteraemic patients, 20 (87.0%) of the 23 patients treated with ertapenem, including one patient with PRSP, and 23 (88.5%) of the 26 treated with ceftriaxone were clinically cured; none had persistent bacteraemia. Cure rates in patients for whom no baseline pathogen was identified were 91.9% and 90.0% for those who received ertapenem and ceftriaxone, respectively.
Safety and local tolerability
Four hundred and seventy-eight patients in the ertapenem group and 379 in the ceftriaxone group received one or more doses of parenteral therapy and were evaluated for AEs. During study therapy (parenteral plus optional oral) and 14 days thereafter, one or more drug-related AEs were reported for 90 (18.8%) patients in the ertapenem group and 86 (22.7%) in the ceftriaxone group; one or more drug-related laboratory AEs were reported for 64 (13.8%) of 464 Table 5 . Two patients, both in the ertapenem group, experienced a seizure during parenteral therapy, one of whom was undergoing adjustment of his epilepsy medication when the seizure occurred.
Parenteral study therapy was discontinued due to a drug-related AE in four (0.8%) patients in the ertapenem group and four (1.1%) in the ceftriaxone group. AEs resulting in discontinuation were: for ertapenem, taste perversion, worsening pneumonia, a seizure and cholecystitis (one patient each); for ceftriaxone, hepatitis, drug-related allergy and elevated liver enzymes (aspartate aminotransferase 248 U/L; alanine aminotransferase 498 U/L) (one patient each), and hoarseness, dyspnoea and hot flashes (one patient).
During study therapy plus the 14 day follow-up period, nine (1.9%) of 478 patients in the ertapenem group and eight (2.1%) of 379 patients in the ceftriaxone group died. None of these deaths was considered to be drug related.
Twenty-nine (6.1%) patients in the ertapenem group and 32 (8.5%) in the ceftriaxone group experienced local symptoms of moderate-to-severe intensity at the injection site, most commonly pain, erythema and tenderness. Of the nine patients in the ertapenem group and five in the ceftriaxone group who received at least one im dose of study drug, none reported a local symptom associated with this route of administration.
Discussion
In this combined analysis of the results of two independent, large comparative trials, ertapenem, 1 g once a day, was equivalent to ceftriaxone, 1 g once a day, for the empirical treatment of CAP judged by the investigator to require initial parenteral antimicrobial therapy. At completion of parenteral therapy, 95% of patients treated with ertapenem and 94% of those treated with ceftriaxone had a favourable clinical response and, at the TOC assessment, 92% of clinically evaluable patients in both treatment groups were cured. In a study of CAP in which patients treated with either ceftriaxone, 1 or 2 g once or twice daily, or cefuroxime axetil, 500 mg twice daily, could also receive iv or oral erythromycin (or doxycycline) if atypical pathogens were suspected or proven, the clinical success rate was 90%. 20 This suggests that in the studies reported here, Legionella species, M. pneumoniae or C. pneumoniae were not important causes of treatment failure; however, this cannot be proved, because the frequency with which these organisms were the causal pathogen was not specifically determined. ii64
Ertapenem was highly effective in all patient populations, including those >65 years of age and those with a PSI of >3. At the TOC assessment, ≥90% of clinically evaluable patients in these two highrisk groups, as well as those aged ≤65 years or with a PSI of ≤3, who were treated with ertapenem were cured. These results, however, should not be generalized to patients with a comorbid condition that resulted in exclusion from these two clinical trials, such as septic shock, severe immune compromise, empyema or lung cancer, because the efficacy of ertapenem for the treatment of such patients with CAP has not been assessed.
In the two trials reported here, an aetiology for the pneumonia could not be determined for 46% of the evaluable patients. Among those for whom an aetiology was identified, S. pneumoniae was the most frequent pathogen, accounting for 44% of all isolates, followed by H. influenzae. These results are consistent with those of other investigators. 20, 21 In the analyses of clinical and microbiological response assessments per pathogen, cure and eradication rates for the ertapenem and ceftriaxone groups were comparable overall and for the major pathogens. The baseline pathogen was eradicated or presumably eradicated in >90% of patients in both treatment groups.
Practice guidelines for the management of adult patients with CAP were published by the Infectious Diseases Society of America (IDSA) in April 1998 22 and revised in 2000. 23 Based on the current guidelines, the preferred antimicrobial therapy for hospitalized patients with CAP on a general hospital ward is cefotaxime or ceftriaxone plus a macrolide or a fluoroquinolone alone, to provide optimal therapy for legionellosis. A potential criticism of the studies reported here is that therapy effective against Legionella spp. and other 'atypical' bacteria was not used. However, in 1998, when these studies were begun, coverage for atypical respiratory pathogens was considered optional in the IDSA guidelines. Nevertheless, because of the potentially serious nature of legionellosis, an attempt was made to exclude patients with this disease by testing urine for Legionella antigen or culturing sputum for the organism. The overall safety and tolerability profiles of ertapenem in both of these studies were similar to those of ceftriaxone. The most common drug-related clinical AE reported for both agents was diarrhoea, and AEs that resulted in discontinuation of either drug were single occurrences. The drug-related laboratory AEs reported most frequently were mild-to-moderate elevations in transaminase levels, which tended to be transient and without clinical consequence. In all ertapenem clinical trials, 16, 17 ,24-28 diarrhoea (5.5%), infused vein complications (3.7%), nausea (3.1%), headache (2.2%), vaginitis in females (2.1%), phlebitis/thrombophlebitis (1.3%) and vomiting (1.1%) were the clinical AEs most commonly reported in patients treated with ertapenem and, as in this analysis, elevated aminotransferase levels were the most frequently reported laboratory AE.
In summary, ertapenem, 1 g once a day, with the option to switch to an oral antimicrobial agent after clinical improvement, was highly effective, both clinically and microbiologically, for the treatment of adult patients with CAP requiring initial parenteral therapy. The results of these studies demonstrate that ertapenem was excellent therapy for CAP in adults with moderate-to-severe disease.
